Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, United Kingdom.
Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, United Kingdom.
Crit Rev Oncol Hematol. 2020 May;149:102921. doi: 10.1016/j.critrevonc.2020.102921. Epub 2020 Mar 3.
Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features. This approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor inhibitor, has been recently investigated in patients with non-clear cell histologies of renal cell cancer. In this review, we have summarized available data on the use of cabozantinib in non-clear renal cell carcinoma.
患有非透明细胞肾细胞癌的患者经常因缺乏治疗方法、非透明组织学肿瘤发病率低以及相应的内在分子特征多样性而被排除在临床试验之外。这种方法导致了在为诊断为非透明细胞肾细胞癌的患者寻找最佳治疗方法方面存在知识差距。卡博替尼是一种有效的多酪氨酸激酶受体抑制剂，最近已在患有肾细胞癌非透明细胞组织学的患者中进行了研究。在这篇综述中，我们总结了卡博替尼在非透明性肾细胞癌中的应用的现有数据。
